7 slides from CorMedix's merger presentation, Nov 10, 2026
Slide 1: Acquisition of Heron Therapeutics Commercial and Pipeline Assets
Acquisition of Heron Therapeutics Commercial and Pipeline Assets November 9, 2026 1
Slide 2: Disclaimer
Disclaimer NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Forward - Looking Statements: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements are often iden
Slide 3: Transaction Overview and Timeline
Transaction Overview and Timeline 3 » Up to $55mm total earn - out payments based on ZYNRELEF ® net sales milestones: $25mm if ZYNRELEF ® net sales exceed $65mm for calendar year 2028, plus an additional $30mm if ZYNRELEF ® net sales exceed $95mm for calendar year 2028 Earn - out Payments » $145 mil
Slide 4: Combined CorMedix and Heron Assets
Combined CorMedix and Heron Assets 4 1. Extends CorMedix’s portfolio into perioperative pain and CINV/PONV, addressing similar call points of hospitals, IDN, and ASC customers covered by the existing field organization 2. Complementary hematology/oncology commercial infrastructure that can be levera
Slide 5: Highlights of Heron Commercial and Pipeline Assets
Highlights of Heron Commercial and Pipeline Assets 5 Established integrated acute care and hematology/oncology supportive care portfolio of four FDA - approved commercial brands, supported by a dedicated hospital and ambulatory surgery center (ASC) sales force with a broad footprint 1 Diversified Q3
Slide 6: Summary of Heron's Commercial Portfolio
Acute Care Products Hematology/Oncology Care Products Dual - acting, extended - release anesthetic that combines local pain relief with anti - inflammatory effects Ready - to - use IV NK1 receptor antagonist offering rapid onset and sustained protection Extended - release 5 - HT3 receptor antagonist
Slide 7: Combined Product Portfolio
Combined Product Portfolio Creates a diversified portfolio with 12 commercial products and multiple near - term pipeline opportunities Commercial Ph III / Registrational Ph II Ph I Pre - Clinical Indication Product Hemodialysis CorMedix Total Parenteral Nutrition (TPN) Hemodialysis (Pediatric label